Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Reporting recommendations for tumor marker prognostic studies (remark).

L M McShane1, D G Altman, W Sauerbrei

  • 1Biometric Research Branch, DCTD, U.S. National Cancer Institute, Bethesda,MD 20892, USA. lm5h@nih.gov

Experimental Oncology
|July 14, 2006
PubMed
Summary

Clinical utility of cancer tumor markers remains limited due to inconsistent research. New reporting guidelines are proposed to improve the reliability and interpretability of tumor marker studies in oncology.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CONSORT 2010 statement: extension checklist for reporting within person randomised trials.

The British journal of dermatology·2019
Same author

'Allocation concealment': the evolution and adoption of a methodological term.

Journal of the Royal Society of Medicine·2018
Same author

[Better Reporting of Interventions: Template for Intervention Description and Replication (TIDieR) Checklist and Guide].

Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany))·2018
Same author

GRIPP2 reporting checklists: tools to improve reporting of patient and public involvement in research.

Research involvement and engagement·2017
Same author

GRIPP2 reporting checklists: tools to improve reporting of patient and public involvement in research.

BMJ (Clinical research ed.)·2017
Same author

Quality control of ultrasound for fetal biometry: results from the INTERGROWTH-21<sup>st</sup> Project.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2017

Area of Science:

  • Oncology
  • Biomarker Research
  • Clinical Diagnostics

Background:

  • Despite extensive research, few tumor markers have achieved clinical utility in oncology.
  • Inconsistent findings and contradictory results plague tumor marker studies, hindering clinical application.
  • Methodological issues and incomplete reporting compromise the quality and generalizability of published tumor marker research.

Purpose of the Study:

  • To address the discrepancies in tumor marker study conclusions.
  • To propose guidelines for rigorous and transparent reporting of tumor marker studies.
  • To enhance the assessment of tumor marker data quality and contextual relevance.

Main Methods:

  • Review of existing challenges in tumor marker research reporting.

Related Experiment Videos

  • Development of comprehensive guidelines for reporting study design, hypotheses, and patient/specimen characteristics.
  • Inclusion of recommendations for assay methods, statistical analysis, data presentation, and discussion elements.

    • Main Results:

    • Identified significant methodologic problems and reporting deficiencies in tumor marker studies.
    • Proposed specific guidelines inspired by successful initiatives like CONSORT and STARD.
    • Emphasized the need for detailed information on study design, methods, and statistical analysis.

    Conclusions:

    • Transparent and complete reporting is crucial for evaluating tumor marker usefulness.
    • Adherence to proposed guidelines will improve the reliability and reproducibility of tumor marker research.
    • Enhanced reporting will enable better judgment of data validity and applicability in clinical oncology.